chr5-78780398-T-G
Variant summary
Our verdict is Likely pathogenic. The variant received 6 ACMG points: 6P and 0B. PM2PM4PP5_Moderate
The NM_000046.5(ARSB):c.1601A>C(p.Ter534Serext*?) variant causes a stop lost change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★).
Frequency
Consequence
NM_000046.5 stop_lost
Scores
Clinical Significance
Conservation
Publications
- mucopolysaccharidosis type 6Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: PanelApp Australia, Genomics England PanelApp, Illumina, Labcorp Genetics (formerly Invitae), G2P, ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Likely_pathogenic. The variant received 6 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000046.5. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| ARSB | NM_000046.5 | MANE Select | c.1601A>C | p.Ter534Serext*? | stop_lost | Exon 8 of 8 | NP_000037.2 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| ARSB | ENST00000264914.10 | TSL:1 MANE Select | c.1601A>C | p.Ter534Serext*? | stop_lost | Exon 8 of 8 | ENSP00000264914.4 | ||
| ARSB | ENST00000521011.1 | TSL:3 | n.566A>C | non_coding_transcript_exon | Exon 3 of 3 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Mucopolysaccharidosis type 6 Pathogenic:1
This sequence change results in a frameshift in the ARSB gene (p.*534Serext*50). While this is not anticipated to result in nonsense mediated decay, it is expected to replace the original stop signal with a serine residue and extend the ARSB protein by an additional 49 amino acids. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with ARSB-related conditions. This variant results in an extension of the ARSB protein. Other variant(s) that result in a similarly extended protein product (p.*534Glnext*50 and p.*534Trpext*50, also known as p.*534W) have been observed in individuals with ARSB-related conditions (PMID: 8144552, 26909334, 30524696). This suggests that these extensions may be clinically significant. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at